Literature DB >> 21527304

Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials.

Humphrey Mulenga1, Sizulu Moyo, Lesley Workman, Tony Hawkridge, Suzanne Verver, Michele Tameris, Hennie Geldenhuys, Willem Hanekom, Hassan Mahomed, Gregory Hussey, Mark Hatherill.   

Abstract

The endpoint definition for infant tuberculosis (TB) vaccine trials should match the TB disease phenotype expected in the control arm of the study population. Our aim was to analyse selected combinations of the clinical, radiological, and microbiological features of pulmonary TB among children investigated under vaccine trial conditions, in order to estimate case frequency for a range of expected TB phenotypes. Two thousand one hundred and eighty five South African children were investigated over a nine-year period (2001-2009). Evidence of TB exposure and classical symptoms were several times more common than chest radiography (CXR) compatible with TB, or positive Mycobacterium tuberculosis culture. Discordance between clinical, radiological, and microbiological features was common in individual children. Up to one third of children with compatible CXR, and up to half the children who were M. tuberculosis culture positive, were asymptomatic. The culture positive rate fell over time, although rates of TB exposure and compatible chest radiography increased. Consequently, the annual incidence of diagnostic combinations that included M. tuberculosis culture fell to <0.2%. However, in this study population (children <2 years of age), annual incidence of the TB disease phenotype that included the triad of TB exposure, symptoms, and compatible CXR, approached 1% (n=848 per 100,000). These findings allow modelling of expected TB case frequency in multi-centre infant TB vaccine trials, based upon benchmarking of diagnostic data against the key indicator variables that constitute the building blocks of a trial endpoint.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21527304     DOI: 10.1016/j.vaccine.2011.04.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.

Authors:  Michele Tameris; Helen McShane; J Bruce McClain; Bernard Landry; Stephen Lockhart; Angelique K K Luabeya; Hennie Geldenhuys; Jacqui Shea; Gregory Hussey; Linda van der Merwe; Marwou de Kock; Thomas Scriba; Robert Walker; Willem Hanekom; Mark Hatherill; Hassan Mahomed
Journal:  Tuberculosis (Edinb)       Date:  2013-02-12       Impact factor: 3.131

2.  Chest Radiographs for Pediatric TB Diagnosis: Interrater Agreement and Utility.

Authors:  G Kaguthi; V Nduba; J Nyokabi; F Onchiri; R Gie; M Borgdorff
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-08-17

3.  The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children.

Authors:  Humphrey Mulenga; Michele D Tameris; Kany Kany A Luabeya; Hennie Geldenhuys; Thomas J Scriba; Gregory D Hussey; Hassan Mahomed; Bernard S Landry; Willem A Hanekom; Helen McShane; Mark Hatherill
Journal:  Pediatr Infect Dis J       Date:  2015-11       Impact factor: 2.129

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.